Asymmetry Capital Management’s Sarepta Therapeutics SRPT Stock Holding History

Asymmetry Capital Management’s Portfolio SRPT Stock Details SRPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-15,016	Closed	-$1.47M	–	36
2020 Q1	$1.47M	Buy	+15,016	New	+$1.72M	1.61%	23
2019 Q3	–	Sell	-11,050	Closed	-$1.68M	–	35
2019 Q2	$1.68M	Buy	+11,050	New	+$1.34M	0.91%	23
2018 Q4	–	Sell	-14,508	Closed	-$2.34M	–	31
2018 Q3	$2.34M	Buy	14,508 +3,259	+29%	+$446K	2.16%	20
2018 Q2	$1.49M	Sell	11,249 -17,884	-61%	-$1.69M	1.46%	24
2018 Q1	$2.16M	Sell	29,133 -13,992	-32%	-$933K	2.7%	12
2017 Q4	$2.4M	Sell	43,125 -61,941	-59%	-$3.28M	3.26%	11
2017 Q3	$4.77M	Sell	105,066 -53,744	-34%	-$2.15M	5.53%	6
2017 Q2	$5.35M	Buy	158,810 +71,630	+82%	+$2.33M	6.35%	3
2017 Q1	$2.58M	Buy	+87,180	New	+$2.7M	3.6%	12

Other funds holding SRPT

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Asymmetry Capital Management's SRPT Position: Q2 2020 in Review

Asymmetry Capital Management sold out of Sarepta Therapeutics (SRPT) in Q2 2020, closing a stake of 15,016 shares — an estimated $1.47M sold.

Asymmetry Capital Management first reported a position in SRPT in Q1 2017 and held it in 9 quarters. The position peaked at $5.35M in Q2 2017. 408 funds tracked by Wall St. Rank hold SRPT as of Q2 2020.

Asymmetry Capital Management reported no remaining Sarepta Therapeutics position as of Q2 2020 after selling out during the quarter.
Asymmetry Capital Management sold 15,016 Sarepta Therapeutics shares in Q2 2020, an estimated $1.47M.
Asymmetry Capital Management first reported a position in Sarepta Therapeutics in Q1 2017 and held it in 9 quarters.
Asymmetry Capital Management's Sarepta Therapeutics position peaked at $5.35M in Q2 2017.
408 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q2 2020.

Based on Asymmetry Capital Management's 13F filing for Q2 2020, filed 6 Aug 2020.